The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes
Open accessAbstract
The availability of an i.v. form of busulfan (Bu) has prompted investigation of administration schedules other than the 4-times-daily dosage commonly used with oral Bu. We have studied an allogeneic stem cell transplantation (SCT) preparative regimen comprising fludarabine (FLU) 50 mg/m2 on days -6 to -2 plus i.v. Bu 3.2 mg/kg daily in a 3-hour infusion on days -5 to -2. The regimen was given to 70 patients aged 15 to 64 years (median, 41 years) with hematologic malignancy. Thirty-six patients (51%) had high-risk malignancy, 28 (40%) had unrelated or genotypically mismatched related donors (alternate donors [AD]) and 29 (41%) received bone marrow rather than blood as stem cell source. Acute GVHD prevention comprised antithymocyte globulin 4.5 mg/kg over 3 days pretransplantation, cyclosporin A, and short-course methotrexate with folinic acid. Hepatic toxicity was transient and there was no clinically diagnosed veno-occlusive disease. Grade II stomatitis occurred in 49 patients (70%) and hemorrhagic cystitis in 9 patients (13%). One patient with subtherapeutic phenytoin levels had a convulsion 8 hours after the third i.v. Bu dose, but no other neurotoxicity was apparent. Incidence of acute GVHD grades II to IV was 8% and incidence of grade III-IV was 3%, with no deaths from this cause. Actuarial incidence of chronic GVHD at 2 years is 38%. There were 2 cases of graft failure in unrelated donor BMT recipients, 1 of which was reversed by asecond transplantation. With a median follow-up of 16 months (range, 6-27 months), transplantation-related mortality at 100 days and 2 years was 2% and 5% for matched related donor (MRD) SCT and 8% and 19% for AD SCT, respectively (P = not significant). Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy. Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively. Pharmacokinetic studies were done using 11 samples with the first and fourth doses of Bu. Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively. Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively. Bu was completely cleared within 24 hours and the day 4 pharmacokinetic values were very similar to those on day 1 for every patient. The cumulative AUC was comparable to the target range established for p.o. Bu. This regimen incorporating once-daily i.v. Bu is convenient to give, is relatively well tolerated, gives predictable blood levels, and deserves further study in circumstances in which cytoreduction as well as immune suppression is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, G. B., Hinds, M. S., Fisher, L. D., Schoch, H. G., Wolford, J. L., Banaji, M., Hardin, B. J., Shulman, H. M., & Clift, R. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-4-199302150-00003 · Cited by 1,202
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
JONES, R. J., LEE, K. S. K., BESCHORNER, W. E., VOGEL, V. G., GROCHOW, L. B., BRAINE, H. G., VOGELSANG, G. B., SENSENBRENNER, L. L., SANTOS, G. W., & SARAL, R. (1987) · Transplantation · doi:10.1097/00007890-198712000-00011 · Cited by 912
Regimen-related toxicity in patients undergoing bone marrow transplantation.
Bearman, S. I., Appelbaum, F. R., Buckner, C. D., Petersen, F. B., Fisher, L. D., Clift, R. A., & Thomas, E. D. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1562 · Cited by 868
Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
Tutschka, P., Copelan, E., & Klein, J. (1987) · Blood · doi:10.1182/blood.v70.5.1382.1382 · Cited by 541
A program package for simulation and parameter estimation in pharmacokinetic systems
D'argenio, D. Z., & Schumitzky, A. (1979) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(79)90025-4 · Cited by 471
Grochow, L. B., Jones, R. J., Brundrett, R. B., Braine, H. G., Chen, T.-L., Saral, R., Santos, G. W., & Colvin, O. M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694339 · Cited by 404
Clift, R., Buckner, C., Thomas, E., Bensinger, W., Bowden, R., Bryant, E., Deeg, H., Doney, K., Fisher, L., & Hansen, J. (1994) · Blood · doi:10.1182/blood.v84.6.2036.2036 · Cited by 358
Slattery, J. T., Clift, R. A., Buckner, C. D., Radich, J., Storer, B., Bensinger, W. I., Soll, E., Anasetti, C., Bowden, R., Bryant, E., et al. (1997) · Blood · doi:10.1182/blood.v89.8.3055 · Cited by 351
Slattery, J. T., Sanders, J. E., Buckner, C. D., Schaffer, R. L., Lambert, K. W., Langer, F. P., Anasetti, C., Bensinger, W., Fisher, L. D., & Appelbaum, F. R. (1995) · PubMed · Cited by 343
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix, S. P., Wingard, J. R., Mullins, R. E., Jerkunica, I., Davidson, T. G., Gilmore, C. E., York, R., Lin, L., Devine, S. M., Geller, R. B., et al. (1996) · PubMed · Cited by 311
Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.
Shulman, H. M., & Hinterberger, W. (1992) · PubMed · Cited by 222
Grochow, L. (1993) · PubMed · Cited by 215
Vassal, G., Deroussent, A., Hartmann, O., et al. (1990) · PubMed · Cited by 180
Russell, J., Chaudhry, A., Booth, K., Brown, C., Woodman, R. C., Valentine, K., Stewart, D., Ruether, J. D., Ruether, B. A., Jones, A. R., et al. (2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70073-5 · Cited by 73
Self-citationCopelan, E., & Deeg, H. J. (1992) · Blood · doi:10.1182/blood.v80.7.1648.1648 · Cited by 63
A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics
Diasio, R. B. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.8.809 · Cited by 34
Cited by
de Lima, M., Couriel, D., Thall, P. F., Wang, X., Madden, T., Jones, R., Shpall, E. J., Shahjahan, M., Pierre, B., Giralt, S., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0414 · Cited by 415
Self-citationKanakry, C. G., O'Donnell, P. V., Furlong, T., de Lima, M. J., Wei, W., Medeot, M., Mielcarek, M., Champlin, R. E., Jones, R. J., Thall, P. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0625 · Cited by 278
Self-citationPorrata, L. F., Ristow, K., Habermann, T., Inwards, D. J., Micallef, I. N., & Markovic, S. N. (2010) · American Journal of Hematology · doi:10.1002/ajh.21849 · Cited by 124
Ben-Barouch, S., Cohen, O., Vidal, L., Avivi, I., & Ram, R. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.238 · Cited by 71
Harris, A. C., Boelens, J. J., Ahn, K. W., Fei, M., Abraham, A., Artz, A., Dvorak, C., Frangoul, H., Freytes, C., Gale, R. P., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016956 · Cited by 33
Metadata
- Authors
- Russell, J. A., Tran, H. T., Quinlan, D., Chaudhry, A., Duggan, P., Brown, C., Stewart, D., Ruether, J. D., Morris, D., Glück, S., Gyonyor, E., & Andersson, B. S.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 8
- Issue
- 9
- Pages
- 468-476
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2042888665
- Cited by
- 286
- References
- 16
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.